Amylin analogues in the treatment of diabetes mellitus: Medicinal chemistry and structural basis of its function

Ernest Adeghate, Huba Kalász

Research output: Contribution to journalReview article

21 Citations (Scopus)

Abstract

Amylin, (islet amyloid polypeptide) or diabetes-associated peptide is co-secreted with insulin in the islet of Langerhans of diabetic patients in approximately 1:100, amylin-insulin ratio. The soluble form of amylin, an analogue of amylin, is used as a supplement to insulin in the treatment of type 1 diabetes. Co-administration of amylin analogue with insulin to patients with type 1 diabetes induced a larger reduction in proprandial hyperglycemia, with a concomitant reduction in the level of glucagon when compared to insulin monotherapy. The actions of amylin analogues appear to be synergistic to insulin, with which it is co-released from insulin-producing beta cells after a meal. Amylin analogues such as pramlintide has been shown to significantly reduce body weight, HbA1c values and even the dosage of insulin. A moderate weight loss can also be achieved in obese patients with or without diabetes. A major side effect of some amylin analogues includes nausea and excitation of the area postrema. This review examines the medicinal chemistry of amylin and its analogues and their effects.

Original languageEnglish
Pages (from-to)78-81
Number of pages4
JournalOpen Medicinal Chemistry Journal
Volume5
Issue numberSPEC. ISSUE 2
DOIs
Publication statusPublished - Nov 9 2011

Keywords

  • Amylin
  • Medicinal chemistry
  • Pramlintide
  • Type 1 diabetes

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology
  • Pharmaceutical Science
  • Drug Discovery

Fingerprint Dive into the research topics of 'Amylin analogues in the treatment of diabetes mellitus: Medicinal chemistry and structural basis of its function'. Together they form a unique fingerprint.

  • Cite this